Combine confidence and speed in diagnosis with efficient and effective treatment to improve outcomes for your patients.
Combine confidence and speed in diagnosis with efficient and effective treatment to improve outcomes for your patients.
For the diagnosis and treatment of coronary artery disease, you are constantly striving to optimize the clinical pathway. This requires solutions that helps you assess patient risks correctly, select the right treatment path for each patient and help deliver effective, efficient treatment in interventional procedures. With clinical efficiency in coronary artery disease care, we offer integrated solutions that work together to help deliver robust clinical results along with connected workflows to drive departmental efficiency.
With the high prevalence of coronary artery disease, a growing number of patients require care. To ensure patients receive high quality of care in an effective and efficient manner, it becomes increasingly important to help optimize the care pathway. We segmented in two phases. The diagnostic phase, in which we are committed to identify those patients that will benefit from having a stent placed and the second phase, where for those selected patients a PCI can be performed effectively and efficiently.
When a patient shows symptoms of CAD, you need a solution that enables you to deliver quick, confident diagnosis by:
Bring confidence and speed to the diagnostic pathway, using EPIQ CVx seamlessly connected to the Cardiac PACS, TOMTEC-ARENA and Intellispace Cardiovascular.
Once a patient arrives at the cath lab, you need a solution that enables efficient, effective procedures by:
Bring more efficiency and effectiveness to the procedure, using the PCI integrated clinical efficiency solution.
1. MARKET INSIGHTS Interventional Cardiology Devices, DRG, United States, 2020. 39% of diagnostic angiographies are followed by PCI. 61% are not; Diagnosis of patients with angina and non-obstructive coronary disease in the catheter laboratory Rahman H., Corcoran D., Aetesam-Ur-Rahman M., Hoole S.P., Berry C., Perera D. Heart 2019 105:20 (1536-1542)
2. Doukky R, Diemer G, Medina A, Winchester DE, Murthy VL, Phillips LM, Flood K, Giering L, Hearn G, Schwartz RG, Russell R, Wolinsky D. Promoting appropriate use of cardiac imaging: no longer an academic exercise.Ann Intern Med. 2017; 166:438–440. doi: 10.7326/M16-2673; Rajiah, P., Abbara, S., & Halliburton, S. S. (2017). Spectral detector CT for cardiovascular applications. Diagnostic and interventional radiology (Ankara, Turkey), 23(3), 187–193. https://doi.org/10.5152/dir.2016.16255
3. There is a shift towards more complex PCI and relatively more acute coronary syndrome (ACS) procedures. Furthermore, more high risk patients are entering the lab with more co-morbidities as well. EuroIntervention 2020;16:536-537. DOI: 10.4244/EIJV16I7A1005. Medscape Cardiologist Compensation Report 2019
4. When an occluded blood vessel that requires treatment is identified, a percutaneous coronary intervention (PCI) is a therapeutic procedure that can be utilized to treat the vessel. A PCI includes angioplasty and positioning a stent across the stenosis to open the vessel. Clinicians conventionally rely on angiography and physiologic measurements of pressure and/or flow, which are not meaningfully connected, to plan a therapeutic intervention. Planning the therapeutic intervention can include selecting various parameters related to the stent, such as positioning, length, diameter, etc. While the collected external cardiac test data, intravascular imaging data, and/or physiologic data can help in planning the therapeutic intervention, their efficacy is limited by the fact they exist as separate tests. For example, clinicians are unable to easily visualize where in the blood vessel the data was collected. Further, physiologic data and external cardiac test data are not integrated in a meaningful way that would allow a clinician to assess the effect of a PCI on, e.g., blood flow to the myocardium. Data on file. Tochterman et al. (2015) - Devices, Systems, and Methods for Vessel Assessment.
5. Reducing procedure time by 17%, with the ability to treat 1 more patient per day with optimized workflow options in image guided therapy and clinical software (Azurion - Philips Azurion Simulation Study 2016 - 12NC 452299123041 - FEB 2017). Results are specific to the institution where they were obtained and may not reflect the results achievable at other institutions.
* It’s the user’s responsibility to ensure that Philips network requirements (such as performance, VPN) for Intellispace Cardiovascular are met.
